Abstract: A method and system for predicting/diagnosing inflammatory diseases, such as, multisystem inflammatory syndrome in children (MIS-C), Kawasaki disease, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), respiratory syncytial virus, an adenovirus, influenza A, B C, or D, and/or parainfluenza in a subject is described.

Abstract: A system and method of controlling a powertrain to protect a high voltage cable by determining a temperature characteristic for a busbar, determining a temperature characteristic adjacent to a component, and determining a current through the high voltage cable. Thereafter, the method reduces an operating characteristic of the powertrain based on the temperature characteristic for the busbar, the temperature characteristic adjacent to the component, and the current.

Abstract: A low speed pre-ignition detection, mitigation, and driver notification system and method utilize a controller to analyze a knock signal from a knock sensor to detect LSPI knock of the engine and in response to detecting the LSPI knock, enrich a fuel/air ratio of the engine and limit a torque output of the engine to a level that is less than a maximum torque output of the engine, and when enriching the fuel/air ratio of the engine and limiting the torque output of the engine does not mitigate the LSPI knock, output at least one message for a driver of the vehicle instructing the driver to take remedial action to mitigate the LSPI knock.

Abstract: A calibration system and method for a spark ignition engine of a vehicle involve artificially weighting engine dynamometer data in high engine load regions and using it to generate training data for an artificial neutral network (ANN). A plurality of ANNs are trained using the training data and the plurality of ANNs are then filtered based on their maximum error to obtain a filtered set of trained ANNs. A statistical analysis is performed on each of the filtered set of trained ANNs including determining a set of statistical metrics for each of the filtered set of trained ANNs and then one of the filtered set of trained ANNs having a best combination of error at high engine loads and the set of statistical error metrics is then selected. Finally, an ANN calibration is generated using the selected one of the filtered set of trained ANNs.

Abstract: Techniques for setting a boost target for a turbocharged engine comprise (i) operating the engine in a scavenging mode such that opening of intake and exhaust valves of cylinders of the engine overlap and (ii) while transitioning the engine in/out of the scavenging mode: determining an engine torque request, creating a torque reserve by setting independent targets for throttle inlet pressure (TIP) and intake manifold absolute pressure (MAP), determining a target TIP based on a target total air charge, engine speed, and a previously-determined target engine volumetric efficiency (VE), controlling a wastegate valve based on the target TIP, determining a target MAP based on the engine torque request, and controlling a throttle valve based on the target MAP. During steady-state scavenging operation, the controller calculates a conventional target TIP based on the engine torque request and controls the wastegate valve based on the conventionally calculated target TIP.

Abstract: An engine bank-to-bank airflow balancing technique includes calculating current and offset volumetric efficiencies of the engine and calculating a slope representing (i) a difference between the offset and current volumetric efficiencies and (ii) a difference between offset and current intake camshaft positions. Based on the respective exhaust gas oxygen concentrations, the technique involves calculating a volumetric efficiency correction corresponding to each cylinder bank and based on the slope and the volumetric efficiency corrections, calculating target intake camshaft position shifts. The technique further involves controlling offsets of the intake camshafts based on the target intake camshaft position shifts.

Abstract: Wnt-1-Induced Secreted Proteins (WISPs) are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides.

Abstract: The invention provides methods and materials for observing protein fragments generated during apoptosis in order to observe this process in mammalian cells. Embodiments of the invention can be used for example to observe apoptosis in order to examine the sensitivity of a mammalian cancer cell to apoptosis inducing agents.

Abstract: Wnt-1-Induced Secreted Proteins (WISPs) are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides.

Abstract: The invention provides methods and materials for observing protein fragments generated during apoptosis in order to observe this process in mammalian cells. Embodiments of the invention can be used for example to observe apoptosis in order to examine the sensitivity of a mammalian cancer cell to apoptosis inducing agents.

Abstract: The present invention is directed to novel polypeptides having homology to the PRO533 protein and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention. The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based on the identification of genes that are amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of the gene product and contribute to tumorigenesis and/or autocrine signaling.

Abstract: Wnt-1-Induced Secreted Proteins (WISPs) are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides.

Abstract: A TNFR homolog, identified as DcR3, is provided. Nucleic acid molecules encoding DcR3, chimeric molecules and antibodies to DcR3 are also provided.

Abstract: A TNFR homolog, identified as DcR3, is provided. Nucleic acid molecules encoding DcR3, chimeric molecules and antibodies to DcR3 are also provided.

Abstract: The present invention is directed to novel polypeptides having homology to the PRO533 protein and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention. The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based on the identification of genes that are amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of the gene product and contribute to tumorigenesis and/or autocrine signaling.

Abstract: The invention concerns composititions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based on the identification of cardiotrophin-1 gene amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of the gene product and contribute to tumorigenesis. Accordingly, the cardiotrophin-1 polypeptide encoded by the amplified gene is believed to be a useful target for the diagnosis and/or treatment (including prevention) of certain cancers, and may act as a predictor of the prognosis of tumor treatment.

Abstract: A process for forming a continuous filament yarn having the surface tactile character of a spun yarn. The process includes passing the cohesive yarn structure through the interior of a rotating sleeve member disposed in surrounding relation to the cohesive yarn structure. The rotating sleeve member includes an abrasive inner surface of diameter greater than the cohesive yarn structure and is adapted to contact the exterior surface of the cohesive yarn structure such that at least a portion of the elongate filaments disposed at the exterior of the cohesive yarn structure are broken. Terminal ends of the broken filaments define an arrangement of outwardly projecting hairs at discrete locations disposed substantially around the circumference of the cohesive yarn structure. An apparatus for carrying out the process is also provided.

Abstract: A process for forming a continuous filament yarn having the surface tactile character of a spun yarn. The process includes passing the cohesive yarn structure through the interior of a rotating sleeve member disposed in surrounding relation to the cohesive yarn structure. The rotating sleeve member includes an abrasive inner surface of diameter greater than the cohesive yarn structure and is adapted to contact the exterior surface of the cohesive yarn structure such that at least a portion of the elongate filaments disposed at the exterior of the cohesive yarn structure are broken. Terminal ends of the broken filaments define an arrangement of outwardly projecting hairs at discrete locations disposed substantially around the circumference of the cohesive yarn structure. An apparatus for carrying out the process is also provided.

Abstract: A TNFR homolog, identified as DcR3, is provided. Nucleic acid molecules encoding DcR3, chimeric molecules and antibodies to DcR3 are also provided.

Abstract: A TNFR homolog, identified as DcR3, is provided. Nucleic acid molecules encoding DcR3, chimeric molecules and antibodies to DcR3 are also provided.